Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Will More Subsidies For New Drugs Be A Core Promise Of New Australian Government?

This article was originally published in PharmAsia News

Executive Summary

A new government in Australia faces a budget gap that will soon bring health care reimbursement with industry focused on a pledge by the Liberal Party to restore the independence of the Pharmaceutical Benefits Advisory Committee.

You may also be interested in...



Battle Over Deferred Drug Listings In Australia: Should Cost-Effective Drugs Always Be Funded?

A storm is brewing in the lead up to Australia's May 10 federal budget over the nation's Pharmaceutical Benefits Scheme, which acts as a single payer to subsidize drug prices and is administered by the government

Medicines Australia Negotiates Lower Off-patent Prices In Exchange For Level Prices For Innovative New Drugs In Newly Announced Federal Budget

PERTH, Australia - As part of the new federal budget announced May 11, Medicines Australia has negotiated price-saving measures with the Australian government that will cut prices on off-patent medicines in exchange for an assurance from the government that innovative prices on drugs will not be cut for four years

Cynata Sets Stage For Global Fujifilm Cell Therapy Deal

Cynata has inched closer to a major global partnership after signing a term sheet with Fujifilm for cell therapy technologies that has been described by analysts as a potentially transformative deal.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC085560

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel